SCHEMBL4337066

SCHEMBL4337066

COc1ccc(NC(=O)OCc2ccc(CC(OC(C)C)C(=O)O)cc2)cc1OC

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 4/20 0.56
FPR2 P25090 1/20 0.49
MAPT P10636 2/20 0.47
LMNA P02545 1/20 0.44
LDHA P00338 1/20 0.44
ALDH1A1 P00352 3/20 0.43
KDM4E B2RXH2 1/20 0.43
CA1 P00915 1/20 0.43
CA2 P00918 1/20 0.43
ACHE P22303 1/20 0.43
KMT2A Q03164 3/20 0.42
MEN1 O00255 2/20 0.42
CYP1A2 P05177 1/20 0.42
MAPK1 P28482 1/20 0.42
CYP2C19 P33261 1/20 0.42
TSHR P16473 1/20 0.42
RAB9A P51151 3/20 0.42
NPC1 O15118 2/20 0.42
POLB P06746 1/20 0.42
ROCK2 O75116 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4334930 0.88 PPARG (0.46) SMN1; SMN2FPR2MAPTLDHAALDH1A1
SCHEMBL4339229 0.87 LMNA (0.45) SMN1; SMN2FPR2MAPTLMNAALDH1A1
SCHEMBL4334222 0.86 SMN1; SMN2 (0.48) SMN1; SMN2FPR2MAPTLMNALDHA
SCHEMBL4335887 0.86 SMN1; SMN2 (0.44) SMN1; SMN2FPR2MAPTLMNAALDH1A1
SCHEMBL4335156 0.86 NPC1 (0.50) SMN1; SMN2FPR2MAPTLMNALDHA
SCHEMBL6723678 0.85 SMN1; SMN2 (0.54) SMN1; SMN2FPR2MAPTLMNAALDH1A1
SCHEMBL4339249 0.85 SMN1; SMN2 (0.46) SMN1; SMN2FPR2MAPTLMNAKDM4E
SCHEMBL4329841 0.84 MTNR1B (0.49) SMN1; SMN2MAPTLMNAALDH1A1KMT2A
SCHEMBL13810706 0.84 SMN1; SMN2 (0.43) SMN1; SMN2MAPTLMNAALDH1A1CA1
SCHEMBL4341654 0.83 PPARG (0.48) SMN1; SMN2MAPTLMNAKMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7544835-B2 Carboxylic acid derivative and salt thereof EISAI R&D MANAGEMENT CO., LTD. (JP) 2009-06-09 US disclosed
US-7544835-B2 Carboxylic acid derivative and salt thereof EISAI R&D MANAGEMENT CO., LTD. (JP) 2009-06-09 US disclosed
US-7544835-B2 Carboxylic acid derivative and salt thereof EISAI R&D MANAGEMENT CO., LTD. (JP) 2009-06-09 US disclosed
US-20040102634-A1 Carboxylic acid derivative and salt thereof EISAI R&D MANAGEMENT CO., LTD. (JP) 2004-05-27 US disclosed
EP-1380562-A1 CARBOXYLIC ACID DERIVATIVE AND SALT THEREOF Eisai Co., Ltd. (JP) 2004-01-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040102634-A1 Carboxylic acid derivative and salt thereof GPR119, IRS1, SLC5A1 SMN1; SMN2 3054/4885FPR2 632/4885MAPT 4654/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.